Spero Therapeutics shared its third quarter results and news about its SP001 study for IgG4-related disease.

Nov 12, 2026, 4:51 PM ETResultsRead the original at SEC EDGAR

Good for SPRO

Spero has $107.9 million in cash, expected to fund operations into the second half of 2029, and plans a Phase 2 study in Q2 2027. The long runway and planned study support SPRO, though the study has not started and Spero committed part of future Utebzi payments to financing.

SPRO · Spero Therapeutics, Inc.

AI read · Good for SPRO

The AI's read

The cash gives Spero time to keep developing its immune-disease program. A Phase 2 study is planned, but it has not started, and this update does not show that SP001 works in patients. Spero also committed part of its expected future Utebzi payments to the financing partner, but it keeps a share of payments remaining after required note payments.

Get alerts for SPRO

Follow Spero Therapeutics, Inc. (SPRO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SPRO

Free on the App Store and Google Play, or on the web.